Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by MirrorWorldManon Jul 24, 2022 12:52pm
163 Views
Post# 34846344

RE:RE:Remember this

RE:RE:Remember thisThat is is one of the reasons why Howie's financial guidance means nothing to investors who have heard it countless times from countless BioTechs. He has been proven wrong on every financial projection so far, why was no update given on the actual R + F revenue vs expected projection on the last quarterly update? We have to wait for the financials, its the only thing in this company that provides actual figures to evaluate this company.  Howie could of least provided an estimate on the cost if his super organization changes and/or how he is expected to pay for it all. But no, you think he would learn. Keep  the guy  to his full time doctor job, hire a business person and remove Howie's decision influence. Do a 5:1 reverse split, provide existing shareholders with a warrant for one additional share at the new price, and Cap the total outstanding shares permitted to be issues for 5 years. Simple. 
<< Previous
Bullboard Posts
Next >>